Danielle Leão Cordeiro de Farias

Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia is characterized by clonal proliferation and progressive accumulation of B-cell lymphocytes that typically express CD19+, CD5+ and CD23+. The lymphocytes usually infiltrate the bone marrow, peripheral blood, lymph nodes, and spleen. The diagnosis is established by immunophenotyping circulating B-lymphocytes, and prognosis is defined by two staging systems (Rai and Binet) established by physical examination and blood counts, as well as by several biological and genetic markers. In this update, we present the recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia for the diagnosis and treatment of chronic lymphocytic leukemia. The following recommendations are based on an extensive literature review with the aim of contributing to more uniform patient care in Brazil and possibly in other countries with a similar social–economic profile.

Splenic marginal zone lymphoma: a literature review of diagnostic and therapeutic challenges

Splenic marginal zone lymphoma (SMZL) is a low-grade B-cell non-Hodgkins lymphoma characterized by massive splenomegaly, moderate lymphocytosis with or without villous lymphocytes, rare involvement of peripheral lymph nodes and indolent clinical course. As a rare disease, with no randomized prospective trials, there is no standard of care for SMZL so far. Splenectomy has been done for many years as an attempt to control disease, but nowadays it has not been encouraged as first line because of new advances in therapy as rituximab, that are as effective with minimal toxicity. Facing these controversies, this review highlights advances in the literature regarding diagnosis, prognostic factors, treatment indications and therapeutic options.

Erratum to “Diagnosis and treatment of chronic lymphocytic leukemia: Recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia” [Rev Bras Hematol Hemoter. 2016;38(4):346–357]

Celso Arrais Rodrigues, Matheus Vescovi Gonçalves, Maura Rosane Valério Ikoma, Irene Lorand-Metze , André Domingues Pereira, Danielle Leão Cordeiro de Farias , Maria de Lourdes Lopes Ferrari Chauffaille, Rony Schaffel, Eduardo Flávio Oliveira Ribeiro, Talita Silveira da Rocha , Valeria Buccheri, Yuri Vasconcelos , Vera Lúcia de Piratininga Figueiredo, Carlos Sérgio Chiattone , Mihoko Yamamoto, on behalf of the Brazilian Group of Chronic Lymphocytic Leukemia a Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil b Hospital Sírio Libanês, São Paulo, SP, Brazil c Fleury Medicina e Saúde, São Paulo, SP, Brazil d Hospital Amaral Carvalho, Jaú, SP, Brazil e Universidade Estadual de Campinas (UNICAMP), São Paulo, SP, Brazil f Universidade Federal de Goiás (UFG), Goiânia, GO, Brazil g Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil h Hospital Santa Lúcia, Brasília, DF, Brazil i A.C Camargo Cancer Center, São Paulo, SP, Brazil j Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brazil k Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, SP, Brazil l Instituto Goiano de Oncologia e Hematologia (INGOH), Goiânia, GO, Brazil m Instituto de Assistência Médica ao Servidor Público Estadual (IAMSPE), São Paulo, SP, Brazil n Hospital Samaritano, São Paulo, SP, Brazil

Chronic lymphocytic leukemia in Brazil: A retrospective analysis of 1903 cases

[1] Garcia-Manero G. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. Am J Hematol. 2015;90: 831–841. [2] Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405. [3] Strupp C, Nachtkamp K, Hildebrandt B, et al. New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): characteristics of refined MDS types. Leuk Res. 2017; 57:78–84. [4] Li Y, Cui R, Qin T, et al. Validation of the WHO 2016 proposals for Myelodysplastic syndromes patients with the presence of ring sideroblasts but without excess blasts. Br J Haematol. 2016; [5] Malcovati L, Papaemmanuil E, Ambaglio I, et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood. 2014;124:1513–1521. [6] Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365:1384–1395.